Ron Seubert, Chairman and CEO

Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.

Eric Kaldjian MD, Chief Medical Officer

Eric directs the scientific and medical applications of RareCyte technology. Eric earned his MD and trained in pathology at the University of Michigan. He was a research fellow at the National Cancer Institute and is certified by the American Board of Pathology. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. Eric’s pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.

Evan Castiglia, Chief Business Officer

Evan is the Chief Business Officer at RareCyte. Previously, he was a portfolio manager for Isis Innovation Ltd. His efforts focused on leading numerous technology commercialization and intellectual property projects based on cutting edge academic research. Prior to his time at Oxford, Evan was the Director of Business Development at the Institute for Systems Medicine Planning Authority in Washington State. He earned his bachelor's degree from Gonzaga University and his MBA from the University of Oxford.